Clinical Trials Browser

Triple Negative Breast Neoplasms × Androgen Antagonists × 90 days × Clear all

NCT07340541 2026-05-20

EVOLVE-BDT

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms